CFM
ACRS icon

Cornerstone Financial Management’s Aclaris Therapeutics ACRS Stock Holding History

Cornerstone Financial Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01K Hold
270
– – ﹤0.01% 979
2025
Q4 		$813 Buy
+270
New +$682 ﹤0.01% 999

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Cornerstone Financial Management's ACRS Position: Q1 2026 in Review

Cornerstone Financial Management held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 270 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #979.

Cornerstone Financial Management first reported a position in ACRS in Q4 2025 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Cornerstone Financial Management held 270 shares of Aclaris Therapeutics worth $1.01K as of Q1 2026.
  • Cornerstone Financial Management left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q1 2026, its #979 holding.
  • Cornerstone Financial Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Cornerstone Financial Management's 13F filing for Q1 2026, filed 8 May 2026.